SymBio
シンバイオ製薬株式会社

October 29, 2026

SymBio Pharmaceuticals Limited
Fuminori Yoshida
Representative Director,
President and Chief Executive Officer
Keiichi Fujiwara
Interim CFO
TEL: +81-3-5472-1125

Notice Regarding Borrowing of Funds

SymBio Pharmaceuticals Limited (the "Company") hereby announces that, pursuant to a resolution of its Board of Directors dated October 8, 2026, it borrowed funds as outlined below.

1. Reason for Borrowing

The funds are being borrowed to cover the Company's working capital, research and development expenses, and other funding needs for its business operations.

2. Details of Borrowing

(i) Lender

(1)	Lender	Fuminori Yoshida
(2)	Amount Borrowed	¥340,000,000
(3)	Interest Rate	0.0% per annum
(4)	Date of Execution	October 15, 2026
(5)	Drawdown Date	October 15, 2026
(6)	Repayment Date	December 30, 2026
(7)	Repayment Method	Lump-sum repayment on the repayment date
(8)	Collateral	None

(ii) Lender

(1)	Lender	Ikuko Yoshida
(2)	Amount Borrowed	¥175,000,000
(3)	Interest Rate	0.0% per annum
(4)	Date of Execution	October 15, 2026
(5)	Drawdown Date	October 15, 2026
(6)	Repayment Date	December 30, 2026
(7)	Repayment Method	Lump-sum repayment on the repayment date
(8)	Collateral	None

3. Impact on Financial Results

This matter will have no impact on the Company's consolidated financial results for the fiscal year ending December 2026.